Limits...
Novel thalidomide analogues display anti-angiogenic activity independently of immunomodulatory effects.

Dredge K, Marriott JB, Macdonald CD, Man HW, Chen R, Muller GW, Stirling D, Dalgleish AG - Br. J. Cancer (2002)

Bottom Line: The anti-tumour effects of thalidomide have been associated with its anti-angiogenic properties.Our results show that both the IMiDs and SelCIDs tested are significantly more potent than thalidomide.Identification of the differential effects of these compounds will enable targeting of such compounds into the appropriate clinical setting.

View Article: PubMed Central - PubMed

Affiliation: Division of Oncology, St. George's Hospital Medical School, Tooting, London SW17 0RE, UK. kdredge@sghms.ac.uk

Show MeSH

Related in: MedlinePlus

The effect of suramin and IMiD-1 on the migratory properties of EA.hy926 cells in an in vitro wound healing assay. Results are expressed as mean number of cells migrating per field. *=P<0.05 versus control (Dunnett's test).
© Copyright Policy
Related In: Results  -  Collection


getmorefigures.php?uid=PMC2376196&req=5

fig5: The effect of suramin and IMiD-1 on the migratory properties of EA.hy926 cells in an in vitro wound healing assay. Results are expressed as mean number of cells migrating per field. *=P<0.05 versus control (Dunnett's test).

Mentions: In order to determine whether a thalidomide analogue with potent anti-angiogenic activity in vitro could be beneficial in a clinical cancer setting, we tested the most potent analogue IMiD-1, in an in vivo tumour challenge model. Daily administration of IMiD-1 (10 or 50 mg kg−1, i.p.) was found to significantly reduce the tumour growth rates (P<0.05) in nude mice and histological examination revealed drug-treated tumours to contain vast regions of necrotic tissue (Figure 5Figure 5


Novel thalidomide analogues display anti-angiogenic activity independently of immunomodulatory effects.

Dredge K, Marriott JB, Macdonald CD, Man HW, Chen R, Muller GW, Stirling D, Dalgleish AG - Br. J. Cancer (2002)

The effect of suramin and IMiD-1 on the migratory properties of EA.hy926 cells in an in vitro wound healing assay. Results are expressed as mean number of cells migrating per field. *=P<0.05 versus control (Dunnett's test).
© Copyright Policy
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC2376196&req=5

fig5: The effect of suramin and IMiD-1 on the migratory properties of EA.hy926 cells in an in vitro wound healing assay. Results are expressed as mean number of cells migrating per field. *=P<0.05 versus control (Dunnett's test).
Mentions: In order to determine whether a thalidomide analogue with potent anti-angiogenic activity in vitro could be beneficial in a clinical cancer setting, we tested the most potent analogue IMiD-1, in an in vivo tumour challenge model. Daily administration of IMiD-1 (10 or 50 mg kg−1, i.p.) was found to significantly reduce the tumour growth rates (P<0.05) in nude mice and histological examination revealed drug-treated tumours to contain vast regions of necrotic tissue (Figure 5Figure 5

Bottom Line: The anti-tumour effects of thalidomide have been associated with its anti-angiogenic properties.Our results show that both the IMiDs and SelCIDs tested are significantly more potent than thalidomide.Identification of the differential effects of these compounds will enable targeting of such compounds into the appropriate clinical setting.

View Article: PubMed Central - PubMed

Affiliation: Division of Oncology, St. George's Hospital Medical School, Tooting, London SW17 0RE, UK. kdredge@sghms.ac.uk

Show MeSH
Related in: MedlinePlus